Replimune (REPL) stock plunged 19% after FDA issued second rejection of RP1 melanoma immunotherapy, citing inadequate trial ...
Replimune (REPL) stock plunged 19% after FDA rejected RP1 melanoma treatment for the second time, citing trial design issues.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results